|Bid||4.00 x 1200|
|Ask||6.97 x 1200|
|Day's Range||5.96 - 6.25|
|52 Week Range||5.71 - 13.70|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.75|
WALTHAM, Mass., Dec. 05, 2018 -- Entasis Therapeutics (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial.
Completed $75.0 million initial public offering in September Reported positive Phase 2 topline results of lead program ETX2514SUL On-track to initiate two Phase 3 clinical.
Entasis Therapeutics (ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced that The New England journal of Medicine (NEJM) published results from a Phase 2 clinical trial evaluating the safety and efficacy of zoliflodacin in patients with uncomplicated gonorrhea. Zoliflodacin represents a new type of oral antibiotic that inhibits DNA synthesis in a manner different from currently approved classes of antibiotic drugs. The clinical trial was sponsored by The National Institute of Allergy and Infectious Disease (NIAID), part of the U.S. National Institutes of Health (NIH).
In a world where superbugs are overpowering various antibiotic drugs, threatening millions of lives, Massachusetts biotechs are fighting hard to ensure the bugs don't become the industry's kryptonite.
WALTHAM, Mass., Oct. 03, 2018 -- Entasis Therapeutics (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial.
The common stock is expected to begin trading on The Nasdaq Global Market on September 26, 2018 under the trading symbol "ETTX." The offering is expected to close on September 28, 2018, subject to customary closing conditions. Credit Suisse and BMO Capital Markets are acting as joint book-running managers for the offering. SunTrust Robinson Humphrey and Wedbush PacGrow are also acting as co-managers for the offering.
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . Viomi Technology Co., Ltd ( VIOT ) will issue 11.4 million shares between $9 and $11 Tuesday on the Nasdaq. Headquartered ...